


Amendments to the Claims

Please amend the claims as follows:

1. (Currently amended) A compound of the formula (I):



wherein

R^1 is hydrogen, halogen, hydroxy, amino, $-\text{CHF}_2$, $-\text{CF}_3$, or $-\text{NHSO}_2\text{CH}_3$;

R^2 , R^3 , and R^4 are each independently selected from the group consisting of:

hydrogen;

halogen;

$-(\text{C}_1\text{-C}_4)\text{alkyl}$;

$-\text{CF}_3$;

amino;

nitro;

$-(\text{CH}_2)_p\text{OR}^{10}$;

$-(\text{CH}_2)_n\text{CN}$;

$-\text{C}(\text{O})\text{NR}^{11}\text{R}^{12}$;

$-\text{C}(\text{O})\text{OR}^{16}$;

$-\text{NHC}(\text{O})\text{R}^{13}$;

$-\text{O}(\text{CH}_2)_o\text{Y}$;

$-\text{SCH}_3$;

$-\text{SO}_2\text{R}^{14}$;

N-morpholino;

N-piperazine or N-piperazine substituted with $(\text{C}_1\text{-C}_4)\text{alkyl}$;

N-pyrrolidine or N-pyrrolidine substituted with $-(\text{CH}_2)_p\text{OH}$;


N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with $-\text{CF}_3$, nitro, amino, halogen, hydroxy, $(\text{C}_1\text{-C}_4)$ alkyl, $(\text{C}_1\text{-C}_4)$ alkoxy or $-\text{NHSO}_2\text{CH}_3$; and

piperidine or piperidine substituted on the nitrogen with $-\text{C}(\text{O})(\text{C}_1\text{-C}_4)$ alkyl;

or R^2 and R^3 may, together with the phenyl ring to which they are attached, form a naphthaline (benzo-fused ring) of the structure:



R^5 , R^6 and R^8 are hydrogen;

R^7 and R^9 are each independently hydrogen or hydroxy;

R^{10} is hydrogen, $(\text{C}_1\text{-C}_4)$ alkyl, $-(\text{CF}_2)_t\text{CHF}_2$, $-(\text{CH}_2)_q\text{NR}^{17}\text{R}^{18}$, $-(\text{CH}_2)_q\text{O}(\text{C}_1\text{-C}_4)$ alkyl, pyrrolidine, or phenyl;

which pyrrolidine may be optionally substituted on the nitrogen with $\text{C}_1\text{-C}_4$ alkyl.

R^{11} and R^{12} are each independently hydrogen or $(\text{C}_1\text{-C}_4)$ alkyl;

R^{13} is $(\text{C}_1\text{-C}_4)$ alkyl, cyclopropyl or $-(\text{CH}_2)\text{-OR}^{19}$;

R^{14} is $(\text{C}_1\text{-C}_4)$ alkyl, $-\text{NR}^{20}\text{R}^{21}$, N-pyrrolidine, phenyl, or $-\text{CF}_3$;

R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , and R^{21} are each independently hydrogen or $\text{C}_1\text{-C}_4$ alkyl;

m is 0, 1, 2, or 3;

n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

q is 1, 2, or 3;

t is 0 or 1;

Y is morpholine, pyrrolidine, or pyrrolidine substituted on the nitrogen by $(\text{C}_1\text{-C}_4)$ alkyl;

~~and the pharmaceutically acceptable salts thereof~~ or a pharmaceutically acceptable salt thereof.

2. (Currently amended) The compound according to **Claim 1**, wherein

R^2 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or phenyl;

R^3 is hydrogen or hydroxy;

R^4 is hydrogen, halogen, nitro, cyano, $-\text{CF}_3$, $-(\text{CH}_2)_p\text{OR}^{10}$, or $-\text{SO}_2\text{R}^{14}$;

p is 0;

R¹⁰ is -CHF₂;

R¹⁴ is (C₁-C₄)alkyl; -CF₃; or -NR²⁰R²¹,

~~and the pharmaceutically acceptable salts thereof~~ or a pharmaceutically acceptable salt thereof.

3. (Currently amended) The compound according to **Claim 2** wherein R⁴ is nitro;
~~and the pharmaceutically acceptable salts thereof~~ or a pharmaceutically acceptable salt thereof.

4. (Original) The compound according to **Claim 3** wherein R² and R³ are hydrogen.

5. (Currently amended) The compound according to **Claim 2** wherein R² is hydrogen;
R³ is hydroxy; and R⁴ is hydrogen;
~~and the pharmaceutically acceptable salts thereof~~ or a pharmaceutically acceptable salt thereof.

6. (Original) The compound according to **Claim 1**, which is selected from the group consisting of:

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-nitrophenyl)-propylamino]-ethyl}-amide,
dihydrochloride salt;

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-cyanophenyl)-propylamino]-ethyl}-amide,
dihydrochloride salt;


7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(2-methyl-4-nitrophenyl)-propylamino]-ethyl}-
amide, dihydrochloride salt;

(S)-7-Phenyl-isoquinoline-5-sulfonic acid [2-(3-hydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-
amide, mesylate salt;

7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-
amide isomer 1, dihydrochloride salt; and

7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-
amide isomer 2, dihydrochloride salt.

7. (Currently amended) A compound of the formula:



wherein R¹ is hydrogen, halogen, hydroxy, amino, -CHF₂ or -NHSO₂CH₃;

R², R³, and R⁴ are each independently:

hydrogen;

halogen;

-(C1-C4)alkyl;

-CF₃;

amino;

nitro;

-(CH₂)_pOR¹⁰;

-(CH₂)_nCN;

-C(O)NR¹¹R¹²;

-C(O)OR¹¹;

-NHC(O)R¹³;

-O(CH₂)_oY;

-SCH₃;

-SO₂R¹⁴;

N-morpholino;

N-piperazine or N-piperazine substituted with (C1-C4)alkyl;

N-pyrrolidine or N-pyrrolidine substituted with -(CH₂)_pOH;


N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with $-\text{CF}_3$, nitro, amino, halogen, hydroxy, (C1-C4) alkyl, (C1-C4)alkoxy or $-\text{NHSO}_2\text{CH}_3$;

piperidine or piperidine substituted on the nitrogen with $-\text{C}(\text{O})(\text{C1-C4})$ alkyl;

or wherein R^2 and R^3 may together with the phenyl ring of formula I form a naphthalene (benzo-fused ring) of the structure:



R^5 , R^6 and R^8 are hydrogen;

R^7 and R^9 are each independently hydrogen or hydroxy;

R^{10} is hydrogen, (C1-C4)alkyl, $-(\text{CF}_2)_n\text{CHF}_2$, $-(\text{CH}_2)_m\text{NR}^{11}\text{R}^{12}$, $-(\text{CH}_2)_o\text{O}(\text{C1-C4alkyl})$, or phenyl;

R^{11} and R^{12} are each independently hydrogen or (C1-C4)alkyl;

R^{13} is (C1-C4)alkyl, cyclopropyl or $-(\text{CH}_2)_o\text{R}^{11}$;

R^{14} is (C1-C4)alkyl, $-\text{NR}^{11}\text{R}^{12}$, N-pyrrolidine, phenyl, or $-\text{CF}_3$;

m is 0, 1, 2, or 3;

n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

Y is morpholine, pyrrolidine or pyrrolidine substituted on the nitrogen by (C1-C4)alkyl;

~~and the pharmaceutically acceptable salts thereof~~ or a pharmaceutically acceptable salt thereof.

8. (Previously presented) A compound selected from the group consisting of:

7-phenyl-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-difluoromethylphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-fluorophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-methylsulfonamido)- isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; ~~and~~

7-(4-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-hydroxy-phenyl)-isoquinoline-5-sulfonic acid {2-[3-(4-nitro-phenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; and

7-phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-nitro-phenyl)-propylamino]-ethyl}-amide, dimesylate.

9. (Previously presented) A pharmaceutical composition comprising a compound of **Claim 1**, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

10. (Cancelled)

11. (Cancelled)